BTK Inhibitors for — CLL and Lymphoma

The choice depends on your specific diagnosis, any existing heart rhythm problems, other medicines you take, and cost. All three main drugs are effective in CLL; the decision often comes down to your cardiac history, since second-generation drugs carry a lower risk of atrial fibrillation. Generic ibrutinib is considerably more affordable in India and is a reasonable first choice where cost is a limiting factor. Ask your oncologist to explain the reasoning for the drug recommended to you — a clear answer to this is entirely reasonable to expect.

In most cases, the treatment continues indefinitely — or until the disease progresses or a side effect makes it necessary to stop. This is different from chemotherapy, which runs in defined cycles and then ends. Many patients stay on a BTK inhibitor for several years. Because the treatment is long-term, tolerability matters as much as efficacy. A drug you can live with comfortably tends to be more effective in practice than one that causes side effects you end up reducing or stopping. It is worth raising this openly with your oncologist when the choice is being made.

Contact your team before your next visit if you notice new or worsening palpitations or a fluttering sensation in your chest, new breathlessness, bleeding that will not stop, bruising that seems disproportionate, or an infection not improving after a few days. These may point to atrial fibrillation, a clotting issue or a serious infection — all of which need assessment sooner rather than later. Mild bruising, joint aches and loose motions are common early on and usually settle. Your team will go through the full list before you start; ask them which symptoms need a same-day call.

Some medicines interact significantly with BTK inhibitors. Certain antifungals, antibiotics and heart medicines can raise the drug level in your blood to an unsafe amount, or lower it so the treatment does not work. Acalabrutinib specifically should not be taken with proton pump inhibitors, which are widely used in India for acidity and reflux. Before starting any new prescription or over-the-counter medicine, tell the prescribing doctor you are on a BTK inhibitor. The same applies to herbal preparations, ayurvedic medicines and supplements — please mention these to your oncology team.

Ibrutinib, acalabrutinib and zanubrutinib are approved by CDSCO and available in India. Generic ibrutinib has made the first-generation drug significantly more accessible on cost. The tablets are dispensed from a pharmacy — you do not come in for infusions. CION centres across Telangana and Andhra Pradesh coordinate prescriptions, blood monitoring and response assessments. Imaging such as PET-CT for response assessment is arranged with partner imaging centres.

If a BTK inhibitor stops controlling the disease, there are other treatment options — this is not the end of the road. Resistance usually develops because a change in the BTK gene prevents the drug from attaching; other drug classes work by different mechanisms and are unaffected by that change. Venetoclax, a BCL-2 inhibitor, is an established next step for many CLL patients. Combination regimens and clinical trials are also possibilities. If your disease progresses, ask your oncologist specifically what the next steps are for your diagnosis — the answer varies depending on which drug was used and for how long.